Novartis Venture Fund and Novo Seeds co-led a $10.4m round for oncology therapy developer Rappta on behalf of corporate parents Novartis and Novo.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

Eli Lilly participated in a $57.6m round that will support the identification and preclinical development of Cedilla's first two small molecule product candidates.

Roivant Sciences, Cigna Ventures and Johnson & Johnson Innovation – JJDC helped push the healthcare data exchange's overall funding to $83m.

Sony Innovation Fund by IGV and Salesforce Ventures have contributed to a $17.1m round for the medical technology developer, bringing its overall funding to roughly $50m.

Novo and Roche are in line for exits from hepatitis drug developer Aligos Therapeutics, which has raised some $230m since it was founded in 2018.

Oxford Nanopore has continued its funding streak with another $108m, bringing this year's haul to more than $208m and its overall total to around $800m.

The Amgen and Illumina-backed genetic sequencing equipment provider brought its funding this year to more than $206m and its overall total to about $800m.

GV, Orient Life and Illumina Ventures are in line to exit cell therapy and vaccine developer SQZ Biotechnologies, which has filed for a $75m offering.